Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort

 
• By Jessica Merrill

The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.

Exit sign
Bluebird is ending its commercial effort in Europe • Source: Alamy

More from Gene Therapies

More from Advanced Therapies